Janssen’s pulmonary hypertension division leader upbeat about the future of PH treatment

A few decades ago, an HIV diagnosis was akin to a death sentence. But with proper treatment including antiretroviral therapy, HIV patients can often expect to have a normal life expectancy.

David Jimenez, former president of Johnson & Johnson’s Janssen Infectious Diseases, is confident that similar breakthroughs can happen in pulmonary hypertension. “We’re not there yet,” said Jimenez, who is now the U.S. president of Janssen’s new Pulmonary Hypertension (PH) division. “That is why our focus is to really improve the lives of patients, and hopefully one day cure it.”

Pulmonary hypertension is a new therapeutic focus for Janssen. Up until recently, Janssen focused on five therapeutic areas: cardiovascular and metabolic diseases, immunology, neuroscience and oncology, and infectious diseases and vaccines.

The company’s 2017 acquisition of Actelion for $30 billion made PH a sixth focus area.

Read more

  • 0